Treatment of steroid-resistant acute renal allograft rejection with alemtuzumab

American Journal of Transplantation

Volumn 13, Issue 1, 2013, Pages 192-196

  Van Den Hoogen, M W F ^a   Hesselink, D A ^b   Van Son, W J ^c   Weimar, W ^b   Hilbrands, L B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Alemtuzumab; antithymocyte globulin; renal allograft rejection; steroid resistant

Indexed keywords

ALEMTUZUMAB; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DRUG COST; FEMALE; GRAFT FAILURE; GRAFT INFECTION; HUMAN; INFUSION RELATED REACTION; KIDNEY ALLOGRAFT REJECTION; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; STEROIDS;

EID: 84871711942     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04328.x     Document Type: Article

References (16)

1. van den Hoogen MW, Hoitsma AJ, Hilbrands LB,. Anti-T cell antibodies for the treatment of acute rejection after renal transplantation. Expert Opin Biol Ther 2012; 12: 1031-1042.
2. Webster AC, Pankhurst T, Rinaldi F, Chapman JR, Craig JC,. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: A systematic review of randomized trial data. Transplantation 2006; 81: 953-965.
3. Uslu A, Nart A,. Treatment of first acute rejection episode: Systematic review of level I evidence. Transplant Proc 2011; 43: 841-846.
4. Hardinger KL,. Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy 2006; 26: 1771-1783.
5. Frampton JE, Wagstaff AJ,. Alemtuzumab. Drugs 2003; 63: 1229-1243.
6. Thomas PG, Ishihara K, Vaidya S, Gugliuzza KK,. Campath and renal transplant rejection. ClinTransplant 2004; 18: 759-761.
7. Csapo Z, avides-Viveros C, Podder H, Pollard V, Kahan BD,. Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients. Transplant Proc 2005; 37: 2032-2036.
8. Upadhyay K, Midgley L, Moudgil A,. Safety and efficacy of alemtuzumab in the treatment of late acute renal allograft rejection. Pediatr Transplant 2012; 16: 286-293.
9. Basu A, Ramkumar M, Tan HP, et al.. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc 2005; 37: 923-926.
10. Clatworthy MR, Friend PJ, Calne RY, et al.. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: Long-term follow-up. Transplantation 2009; 87: 1092-1095.
11. Hanaway MJ, Woodle ES, Mulgaonkar S, et al.. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909-1919.
12. Rai K, Hallek M,. Future prospects for alemtuzumab (MabCampath). Med Oncol 2002; 19 (Suppl): S57-S63.
13. Racusen LC, Solez K, Colvin RB, et al.. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
14. Bloom DD, Hu H, Fechner JH, Knechtle SJ,. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 2006; 81: 81-87.
15. Margreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller C, Calne RY,. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: Results of a prospective randomized trial. Am J Transplant 2008; 8: 1480-1485.
16. Peleg AY, Husain S, Kwak EJ, et al.. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44: 204-212.